Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from chemotherapy-based treatment toward increasingly targeted and personalized combination therapies. With the uptake of new therapies and combinations, we expect the AML market to grow substantially over the forecast period. Additionally, several drug developers are engaged in the race to launch new therapies in the AML market. The late-phase pipeline is active and spans several drug classes, including reformulations of existing drugs, novel chemotherapies, novel antibody technologies, and small molecules.
Questions Answered:
How will second-generation FLT3 inhibitor vie for a share of the FLT3-mutation-positive market?
How will Venclexta perform in the sizable and highly lucrative newly diagnosed patient population ineligible for intensive treatment?
What will be the uptake of oral azacitidine as a maintenance treatment in AML? How do oncologists view this agent?
How do oncologists view Vyxeos, and how will the agent perform in AML?
Product DescriptionDisease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. Geographies: United States, EU5, Japan. Primary research: 20 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other DRG research. Epidemiology: Diagnosed incident cases of AML by country; clinically and commercially relevant drug-treatable populations. Forecast: 10-year, annualized drug-level sales and patient shares of key AML therapies through 2029, segmented by brands/generics, age, and line of therapy. Emerging therapies: Phase III/PR: 11 drugs; coverage of selected Phase II and Phase I products.